MedWatch

2curex tests main product in new cancer disease

The stock exchange listed, Danish company 2curex expands its trials with its tool IndiTreat, which can predict the optimal drug for cancer patients. Now the product is also being tested in ovarian cancer.

Foto: /ritzau/Liselotte Sabroe

2curex is looking at new cancer diseases and is expanding clinical trials on the company's main product, the clinical tool IndiTreat, to include treatment of ovarian cancer.

This is happening in collaboration with the University Medical Center Hamburg-Eppendorf (UKE) from Germany and Rigshospitalet in Denmark. The partners have taken the initiative to expand the trials, and therefore the majority of the costs are covered.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Headhunter: Afgående Leo-boss var et flop

Det var et fejlskud at ansætte Catherine Mazzacco som adm. direktør for Leo Pharma, vurderer headhunter, der ser afgangen som et naturligt skridt forud for børsnoteringen af Leo Pharma. Til at styre den proces i mål vil bestyrelsen efter alt at dømme skulle til udlandet for at finde den rette profil, lyder det videre.

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier